STELARA — Sales to customers (Note 9)
Johnson & Johnson STELARA — Sales to customers (Note 9) decreased by 46.7% to $656.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 59.6%, from $1.63B to $656.00M. Over 4 years (FY 2021 to FY 2025), STELARA — Sales to customers (Note 9) shows a downward trend with a -9.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market demand and successful commercialization, while a decrease may signal patent expirations, increased competition, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total net revenue generated from the sale of a specific flagship pharmaceutical product to ex...
Peer comparison
Comparable to revenue reporting for specific blockbuster drugs or key therapeutic franchises at other large-cap pharmaceutical companies.
jnj_segment_stelara_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.27B | $2.38B | $2.33B | $2.29B | $2.60B | $2.45B | $2.39B | $2.44B | $2.80B | $2.86B | $2.75B | $2.45B | $2.89B | $2.68B | $2.35B | $1.63B | $1.65B | $1.57B | $1.23B | $656.00M |
| QoQ Change | — | +4.6% | -1.9% | -2.0% | +13.6% | -5.8% | -2.5% | +2.4% | +14.4% | +2.4% | -3.9% | -11.0% | +17.7% | -7.2% | -12.2% | -30.8% | +1.7% | -5.0% | -21.7% | -46.7% |
| YoY Change | — | — | — | — | +14.3% | +3.0% | +2.3% | +6.8% | +7.6% | +16.9% | +15.3% | +0.3% | +3.1% | -6.6% | -14.7% | -33.7% | -42.7% | -41.3% | -47.6% | -59.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's stelara — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported stelara — sales to customers (note 9) of $656.00M in Q1 2026.
- How has Johnson & Johnson's stelara — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's stelara — sales to customers (note 9) decreased by 59.6% year-over-year, from $1.63B to $656.00M.
- What is the long-term trend for Johnson & Johnson's stelara — sales to customers (note 9)?
- Over 4 years (2021 to 2025), Johnson & Johnson's stelara — sales to customers (note 9) has grown at a -9.7% compound annual growth rate (CAGR), from $9.13B to $6.08B.
- What does stelara — sales to customers (note 9) mean?
- The total revenue earned from sales of a specific pharmaceutical product.